Mirum Pharmaceuticals Initiates Phase II Trial of MRM-3379 for Fragile X Syndrome
核心洞察
Mirum Pharmaceuticals has enrolled the first patient in the BLOOM phase II study evaluating MRM-3379, a PDE4D (搜索) inhibitor, for treating Fragile X syndrome (搜索), marking a significant milestone for this rare genetic neurocognitive disorder.
MRM-3379 is an orally available, brain-penetrant selective phosphodiesterase-4D inhibitor designed to enhance cAMP signaling, with preclinical studies showing improvements in cognitive and behavioral symptoms linked to FXS.
The study targets male participants with confirmed genetic diagnosis of FXS, addressing a critical unmet medical need as no approved therapies currently exist for this condition affecting approximately 50,000 males in the US and Europe.
Mirum Pharmaceuticals has enrolled the first patient in its phase II BLOOM study evaluating MRM-3379, a selective PDE4D (搜索) inhibitor, for treating Fragile X syndrome (搜索) (FXS). This milestone represents a significant step forward in addressing a critical unmet medical need, as no approved therapies currently exist for this rare genetic neurocognitive disorder.
Study Design and Objectives
The BLOOM study will evaluate the safety, tolerability and potential clinical benefit of MRM-3379 in male participants with a confirmed genetic diagnosis of FXS. The primary endpoint focuses on safety and tolerability, with top-line data expected in 2027. This represents the first clinical trial to advance a potential treatment specifically targeting the underlying biology of Fragile X syndrome (搜索).
Understanding Fragile X Syndrome
Fragile X syndrome (搜索) is caused by a mutation in the FMR1 (搜索) gene and represents the most common inherited form of intellectual disability (搜索) and autism (搜索). The condition affects approximately 1 in 4,000 males and 1 in 8,000 females globally, with around 50,000 males affected in the United States and Europe. The syndrome manifests in developmental delays, learning difficulties, anxiety, hyperactivity and autistic-like behaviors.
MRM-3379 Mechanism and Development
MRM-3379 is an orally available, highly brain-penetrant, selective phosphodiesterase-4D (PDE4D (搜索)) inhibitor designed to enhance cAMP signaling. The compound was originally discovered by scientists at Dart Neuroscience (搜索) and has been advanced through Phase 1 clinical development. PDE inhibitors aim to elevate cyclic AMP (cAMP) levels, rebuild neural signaling networks and restore synaptic plasticity—a pathway particularly relevant in Fragile X and other intellectual and developmental disabilities.
Preclinical data, including results from an FMR1 (搜索) knockout mouse model of Fragile X syndrome (搜索), suggest that MRM-3379 improves cognition and alleviates behavioral deficits across multiple domains. The compound has demonstrated improvements across several cognitive and behavioral symptoms linked to FXS, along with favorable tolerability in healthy volunteers during preclinical studies.
Licensing Partnership
In October, Mirum in-licensed worldwide rights to develop and commercialize MRM-3379 from Enthorin Therapeutics (搜索) and Dart Neuroscience (搜索). The entry of MRM-3379 into Fragile X patient trials represents the culmination of over a decade of scientific research and development by clinicians and scientists at Enthorin and Dart Neuroscience.
Clinical Significance
If successfully developed, MRM-3379 may offer a novel approach to improving cognition and daily function for patients living with FXS. The initiation of this phase II trial marks a critical advancement in the field, as it addresses the significant gap in treatment options for patients and families affected by this neurodevelopmental disorder (搜索).
The BLOOM study's focus on male participants reflects the X-linked inheritance pattern of FXS, where males are more severely affected due to having only one X chromosome. The study's design targeting confirmed genetic diagnosis ensures precise patient selection for evaluating the compound's therapeutic potential in this specific population.